What question did this study set out to answer?

Develop and internally validate a scoring system evaluating predilation, sizing, and post-dilation (PSP score) to predict cardiac adverse events following everolimus-eluting bioresorbable scaffold implantation.

April 1, 2017EuroIntervention

Predilation, sizing and post-dilation scoring in patients undergoing everolimus-eluting bioresorbable scaffold implantation for prediction of cardiac adverse events: development and internal validation of the PSP score

View Full Paper

Ask AI

Bookmark

Why the study?

Does the PSP score predict device-oriented cardiac events in patients undergoing everolimus-eluting bioresorbable scaffold implantation?

Key Points

Develop and internally validate a scoring system evaluating predilation, sizing, and post-dilation (PSP score) to predict cardiac adverse events following everolimus-eluting bioresorbable scaffold implantation.
Evaluated procedural metrics—including predilation, scaffold sizing, and post-dilation technique—in patients receiving everolimus-eluting bioresorbable scaffolds.
Tracked clinical outcomes, specifically device-oriented composite endpoints (DoCE), through one-year follow-up.
The PSP-1 score served as an independent predictor of device-oriented composite endpoints at one-year follow-up.
External validation and prospective trials are required to establish the clinical utility and generalizability of the score.

Structured PICO

Does the PSP score predict device-oriented cardiac events in patients undergoing everolimus-eluting bioresorbable scaffold implantation?

Population

Patients undergoing everolimus-eluting bioresorbable scaffold implantation

Intervention

Predilation, sizing and post-dilation (PSP) scoring

Outcome

Device-oriented cardiac events (DoCE) at one-year follow-upcomposite

The newly developed PSP score independently predicts device-oriented cardiac events at 1 year following bioresorbable scaffold implantation.

Limitations

External validation and prospective studies are needed to determine clinical usefulness

Implication

May support PSP-1 for post-scaffold risk stratification; hypothesis-generating, requires prospective validation.

Abstract

At one-year follow-up, the PSP-1 score was an independent predictor of DoCE. External validation and prospective studies are needed to determine the clinical usefulness of this score.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Ortega‐Paz et al. (2017) studied this question.

synapsesocial.com/papers/69d8d20533ca018b39ae41dd https://doi.org/10.4244/eij-d-16-00974

View Full Paper

Ask AI

Bookmark

Implication

May support PSP-1 for post-scaffold risk stratification; hypothesis-generating, requires prospective validation.

Abstract

At one-year follow-up, the PSP-1 score was an independent predictor of DoCE. External validation and prospective studies are needed to determine the clinical usefulness of this score.

Predilation, sizing and post-dilation scoring in patients undergoing everolimus-eluting bioresorbable scaffold implantation for prediction of cardiac adverse events: development and internal validation of the PSP score

Key Points

Structured PICO

Limitations

Implication

Abstract

Discussion

Cite This Study

Predilation, sizing and post-dilation scoring in patients undergoing everolimus-eluting bioresorbable scaffold implantation for prediction of cardiac adverse events: development and internal validation of the PSP score

Key Points

Structured PICO

Limitations

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading